A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion

Jeffrey G. Supko, Joseph P. Eder, Jeffrey W. Clark et al.|Cancer Chemotherapy and Pharmacology|2000

Cited by 30